are potent modulators of metabolic enzymes. Hence, potential drug-drug interactions (DDIs) may occur between these 2 drugs and antiretrovirals. Here, we aimed to assess the relevance of these drug-drug interactions in real-life clinical settings.
Patients treated concomitantly with carbamazepine
and antiretrovirals for at least 3 months were considered. Data on therapeutic drug monitoring
(TDM) of both antiepileptic and antiretrovirals as trough concentrations were collected. HIV
-infected patients not concomitantly treated with antiepileptic drugs and who underwent TDM for antiretrovirals in the previous 2 years were considered as controls.
-positive patients prescribed carbamazepine
were identified. All the TDM evaluations for carbamazepine
that resulted were within the therapeutic ranges. TDM results of darunavir measured in these patients were comparable with values usually measured in the control group. Conversely, the trough concentrations for atazanavir and dolutegravir demonstrated significantly lower values when compared with values usually measured in HIV
-infected patients not treated with antiepileptic drugs (190 ± 91 versus 546 ± 380 ng/mL; −65%, P
< 0.001; 191 ± 78 versus 1096 ± 510 ng/mL; −83%, P
< 0.001, respectively).
Co-administration of carbamazepine
with atazanavir or dolutegravir should be avoided owing to the potential risk of virological failure; in case of these 2 drugs, the adoption of TDM is strongly advisable, eventually combining with increased antiretroviral doses.